Delek US Holdings, Inc. (DK) Reaches $26.55 After 3.00% Up Move; Celgene (CELG) Has 1.34 Sentiment

October 9, 2017 - By Kurt Siggers

Celgene Corporation is an integrated global biopharmaceutical company. The company has market cap of $108.81 billion. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. It has a 43.25 P/E ratio. The Company’s commercial-stage products include REVLIMID , POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide).

The stock of Delek US Holdings, Inc. (NYSE:DK) is a huge mover today! About 288,785 shares traded. Delek US Holdings, Inc. (NYSE:DK) has risen 89.96% since October 9, 2016 and is uptrending. It has outperformed by 73.26% the S&P500.The move comes after 8 months positive chart setup for the $2.13B company. It was reported on Oct, 9 by Barchart.com. We have $27.35 PT which if reached, will make NYSE:DK worth $63.90M more.

Since May 22, 2017, it had 0 insider purchases, and 10 sales for $6.18 million activity. Yemin Ezra Uzi had sold 202,806 shares worth $5.15M. 20,000 shares were sold by Ginzburg Assi, worth $520,000. $20,959 worth of Delek US Holdings, Inc. (NYSE:DK) was sold by Page Mark T.. 1,700 shares were sold by LEONARD CHARLES H, worth $43,308. Miller Anthony L. also sold $18,844 worth of Delek US Holdings, Inc. (NYSE:DK) on Friday, May 26. Shares for $19,750 were sold by Holmes Donald Norman.

Investors sentiment decreased to 1.01 in 2017 Q2. Its down 0.26, from 1.27 in 2017Q1. It turned negative, as 40 investors sold Delek US Holdings, Inc. shares while 34 reduced holdings. 37 funds opened positions while 38 raised stakes. 54.04 million shares or 6.77% less from 57.96 million shares in 2017Q1 were reported. First Midwest Fincl Bank Division owns 0.04% invested in Delek US Holdings, Inc. (NYSE:DK) for 13,732 shares. Alberta – Canada-based Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Investment Mgmt has invested 0% in Delek US Holdings, Inc. (NYSE:DK). State Bank Of Nova Scotia reported 0.05% of its portfolio in Delek US Holdings, Inc. (NYSE:DK). State Street Corp holds 0.01% of its portfolio in Delek US Holdings, Inc. (NYSE:DK) for 2.32M shares. Cornerstone Mgmt Ltd holds 0.04% or 184,066 shares in its portfolio. Luminus Mngmt Limited Liability stated it has 400,000 shares or 0.22% of all its holdings. Thrivent Fincl For Lutherans stated it has 0.01% in Delek US Holdings, Inc. (NYSE:DK). Tiaa Cref Inv Management Limited Liability has 0.04% invested in Delek US Holdings, Inc. (NYSE:DK) for 1.93M shares. Dimensional Fund Limited Partnership owns 0.06% invested in Delek US Holdings, Inc. (NYSE:DK) for 5.22M shares. Nine Chapters Capital Mgmt Ltd Limited Liability Company holds 3.28% of its portfolio in Delek US Holdings, Inc. (NYSE:DK) for 13,100 shares. Moreover, Chicago Equity Partners has 0.13% invested in Delek US Holdings, Inc. (NYSE:DK). Sei Invs has invested 0% in Delek US Holdings, Inc. (NYSE:DK). Meeder Asset Mgmt Incorporated reported 2,535 shares or 0.01% of all its holdings. Cubist Systematic Strategies Limited Liability Corp invested in 0.09% or 54,657 shares. Anchor Bolt Limited Partnership holds 0.45% or 438,248 shares in its portfolio.

Analysts await Delek US Holdings, Inc. (NYSE:DK) to report earnings on October, 30. They expect $0.50 EPS, up 377.78% or $0.68 from last year’s $-0.18 per share. DK’s profit will be $40.11 million for 13.28 P/E if the $0.50 EPS becomes a reality. After $-0.40 actual EPS reported by Delek US Holdings, Inc. for the previous quarter, Wall Street now forecasts -225.00% EPS growth.

Among 18 analysts covering Delek US Holdings (NYSE:DK), 4 have Buy rating, 0 Sell and 14 Hold. Therefore 22% are positive. Delek US Holdings had 50 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of Delek US Holdings, Inc. (NYSE:DK) earned “Outperform” rating by RBC Capital Markets on Wednesday, August 5. Howard Weil maintained Delek US Holdings, Inc. (NYSE:DK) on Tuesday, August 30 with “Sector Perform” rating. The stock of Delek US Holdings, Inc. (NYSE:DK) earned “Sector Outperform” rating by Howard Weil on Tuesday, December 15. The stock has “Hold” rating by Scotia Capital on Wednesday, April 12. On Tuesday, October 11 the stock rating was downgraded by Credit Suisse to “Neutral”. The firm earned “Outperform” rating on Wednesday, December 16 by Raymond James. The rating was maintained by Piper Jaffray on Friday, September 16 with “Neutral”. Bank of America upgraded Delek US Holdings, Inc. (NYSE:DK) on Thursday, January 5 to “Neutral” rating. The rating was downgraded by Wolfe Research on Monday, November 14 to “Peer Perform”. The stock of Delek US Holdings, Inc. (NYSE:DK) has “Sector Perform” rating given on Monday, July 11 by Howard Weil.

Since January 1, 0001, it had 0 insider buys, and 3 selling transactions for $2.36 million activity.

Birchview Capital Lp holds 53.25% of its portfolio in Celgene Corporation for 775,051 shares. Oaktop Capital Management Ii L.P. owns 2.09 million shares or 49.74% of their US portfolio. Moreover, Hellman Jordan Management Co Inc Ma has 20.91% invested in the company for 74,979 shares. The New Jersey-based Selkirk Management Llc has invested 18.27% in the stock. Fcg Advisors Llc, a New Jersey-based fund reported 352,094 shares.

Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on October, 26. They expect $1.72 earnings per share, up 23.74% or $0.33 from last year’s $1.39 per share. CELG’s profit will be $1.35B for 20.22 P/E if the $1.72 EPS becomes a reality. After $1.68 actual earnings per share reported by Celgene Corporation for the previous quarter, Wall Street now forecasts 2.38% EPS growth.